DOCSLIB.ORG

CRO Service Specialized in NASH-HCC -Proprietary STAMTM Mouse Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CRO Service Specialized in NASH-HCC -Proprietary STAMTM Mouse Model CRO service specialized in NASH-HCC -Proprietary STAMTM mouse model- SMC Laboratories, Inc. smccro-lab.com Ver. 2021.1 1 Overview 1 Company 2 Rationale: NASH 3 STAMTM: Proprietary model for NASH-HCC 4 Pharmacological study 5 CRO service -2- Facts at a glance ■ Founded in October 2006 ■ A privately-held non-clinical CRO based in Tokyo, Japan; specialized in research on fibrosis and inflammation ■ CRO services - Non-clinical pharmacology - One of the leading CRO in liver research with Proprietary NASH-HCC (STAMTM) Model - In vivo disease models for metabolic disorders, inflammation, fibrosis and tumor - Histological imaging services - Histological scoring: NAFLD activity score, fibrosis and inflammation scores etc. -3- 2 CRO expertise: Leading CRO in NASH/HCC Over 600 clients worldwide Over 110 peer-reviewed papers and presentations 15 successful CTA packages The number of clients Region 550 500 450 Europe 400 Japan 350 US・ 300 Canada JPN 250 200 North Asia America 150 Europe 100 Asia・ 50 Oceania 0 2011 2012 2013 2014 (% of the customers) 2015 2016 2017 2018 (year) -4- CRO capability: ■ Facility - Accreditation by MEXT* - Sponsor audit (QAU) - Animal welfare audit by global pharmaceuticals ■ SPF-grade animal room: - 2080 mice ■ CRO science team: - 10 full-time researchers - 5 visiting scientists (MD, PhD) - 3 external pathologists ■ Equipment: - CT system (In vivo) - Endoscopy (In vivo) - Confocal microscopy - Dry-chemistry analyzer - Real-time PCR - Multi-mode microplate reader - And more… *MEXT: Ministry of Education, Culture, Sports, Science and Technology -5- CRO portfolio: Nonclinical disease models Available Services 1. Pharmacology study → Efficacy of existing drugs/drug candidates 2. Delivery of mouse samples (organs, plasma/serum, fecal etc.) → Target discovery and validation → Biomarker discovery and validation Disease model lineup ■ STAMTM: Premium model for NASH-HCC (mice) ■ Other inflammation/fibrosis/cancer models (mice) CCl4 BLM ・Liver fibrosis: CCl4 model, BDL model ・Acute liver failure : CCl4 model, Concanavalin A model D-gal/LPS model, TAA model ・Pulmonary fibrosis: BLM-induced lung fibrosis model Sirius red CT (Lung) ・Skin fibrosis: BLM-induced skin fibrosis model UUO DSS ・Renal diseases: UUO-induced renal fibrosis model Adenine-induced nephropathy model ・Renal diseases: Adriamycin-induced nephropathy model ・IBD: DSS-induced colitis model PAS Endoscopy ・Liver cancer: DEN-CCl4 liver cancer model ・Alzheimer’s disease: icv-STZ model -6- Overview 1 Company 2 Rationale: NASH 3 STAMTM: Proprietary model for NASH-HCC 4 Pharmacological study 5 CRO service -7- Why focus on NASH? ■ High prevalence US: NAFLD 55-155 million NASH 15-50 million JP: NAFLD 10~ million* NASH 2~ million* ■ Sharp increase in pediatric patients ■ Progression to HCC (NASH) ■ No established treatment ■ Economic loss -1 billion USD per year (US) Causes of Death in Japanese Diabetics ■ Comorbidity of diabetes - 1 in 8 diabetes patients die of liver fibrosis/HCC. - Over 30% of diabetes patients show liver injury. ■ NASH increases the risk of CVD *Japan Study Group of NAFLD (JSG-NAFLD) 2008-2011 Hotta N., et al., Journal of the Japan Diabetes Society 50:47, 2007 -8- NASH: clinical process and diagnosis Steatosis NASH Fibrosis HCC 10-30% 10-29%** 4-27%** (NASH to fibrosis) (NASH to HCC) 6.3 – 33% (med. 20%) 3 – 5% Similar to HCV in general population* in general population* Screening/Initial evaluation US Diagnosis -fatty change NAFL -chronic change NAFLD Liver biopsy NASH +/- fibrosis ALT↑ Imaging (CT, MR..) +/- HCC HBsAg (-) HCV (-) NAFLD fibrosis score ANA (-)~low Alcohol (-)~low US: Ultra Sound, CT: Computed Tomography, MR: Magnetic Resonance *CVD: Cardiovascular*Chalasani N., disease et al., Gastroenterology 142:1592, 2012 (AGA guideline), **Cohen J., et al., Science 332:1519, 2011 -9- No approved drugs: AGA guideline 2012 Intervention Recommendations GRADE* S Q Lifestyle ● Up to 10% weight loss may be needed to improve necroinflammation 1 B Metformin ● Metformin is not recommended as a specific treatment in adults with NASH 1 A ● Pioglitazone can be used to treat steatohepatitis in patients with biopsy-proven NASH Tiazolidinediones 1 B ● Long term safety and efficacy is not established ● α-tocopherol (800 IU/day) improves liver histology in non-diabetic adults with biopsy-proven 1 B Vitamin E NASH → First-line pharmacotherapy for this patient population ● NOT in other patient populations, pending further evidence supporting this efficacy 1 C UDCA ● UDCA is not recommended for the treatment of NAFLD/NASH 1 B ● Omega-3 fatty acids may be considered as first-line therapy for hypertriglycemia in patients Omega-3 fatty acid 1 B with NAFLD, but it is premature to recommend them ● Statins can be used to treat dyslipidemia in patients with NAFLD/NASH, but should not be Statin 1 B used to specifically treat NASH, pending evidence from RCTs *GRADE: Grading of Recommendations , Assessment, Development and Evaluation S (Strength of recommendation): 1 = strong, 2 = weak Q (Quality of evidence): A = high, B = moderate, C = low Chalasani N., et al., Gastroenterology 142:1592, 2012 (AGA guideline) -10- Drug candidates in clinical trials Company Drug Target Route Period Endpoint Stage Intercept: OCA - 18 months 1)Histology P3 FXR REGENERATE study 2)Fibrosis and NASH GENFIT: Elafibranor PPARα /δ Oral 72 weeks 1)Histology P3 RESOLVE-IT study 2)Fibrosis Galmed Aramchol Synthetic fatty acid Oral 52 weeks 1)% change in liver triglyceride P3 bile conjugate 2)Fibrosis, NAS etc. Allergan: Cenicriviroc (CVC) CCR5/CCR2 antagonist Oral 1 year 1)Fibrosis P3 AURORA study Allergan: Cenicriviroc (CVC) CCR5/CCR2 antagonist Oral 1 year 1)NAS P2 CENTAUR study Novartis/Allergan: Tropifexor (LJN452) FXR Oral 48 weeks 1) Number of participants with Adverse Events P2 TANDEM study Cenicriviroc (CVC) CCR5/CCR2 antagonist Oral 2) Fibrosis Novo Nordisk: Liraglutide GLP-1 SC 48 weeks 1)Histology P2 LEAN study 2)NAS Conatus: Emricasan Caspase inhibitor Oral 72 weeks 1)Fibrosis P2 ENCORE-NF study 2)NAS Gilead GS-9674 FXR Oral 24 weeks plus 30 1)Overall safety profile P2 days Gilead GS-0976 ACC Oral 24 weeks plus 30 1)Overall safety profile P2 days Gilead Simtuzmab Loxl2 SC 96 weeks 1)Fibrosis P2 2)Safety BMS BMS-986036 FGF21 - 16 weeks 1)Change in percent hepatic fat fraction P2 2) Average concentration Galectin GR-MD-02 Galectin-3 IV 16 weeks 1)LiverMultiScan P2 Therapeutics 2)MR-elastography NGM NGM282 FGF19 - 12 weeks 1)Change in absolute liver fat content P2 2)Change in percentage liver fat content Cempra Solithromycin Ketolide antibiotic Oral 13 weeks 1)NAS P2 2)Changes in steatosis Boehringer Ingelheim BI 1467335 SSAO/VAP-1 Oral 12 weeks 1)Target enzyme activity relative to baseline in P2 percent 2)Relative to ALT, AST, AP, GGT ,cleaved CK18, total CK18 change from baseline -11- Source: clinicaltrial.gov Overview 1 Company 2 Rationale: NASH 3 STAMTM: Proprietary model for NASH-HCC 4 Pharmacological study 5 CRO service -12- Advantages of STAMTM: Proprietary NASH-HCC model ■ Distinct from existing NAFL/diabetes models, STAMTM model represents the patient population who develops HCC among NAFL/diabetic populations. - By comparing with existing NAFL/diabetes models which never show fibrosis/HCC, 1) novel factors underlying worse prognosis can be investigated and 2) risk factor-modifying medicine/personalized medicine can be investigated in diabetes/metabolic disease fields. ■ Clear onset of NAFL/NASH and 100% progression to fibrosis/HCC without exception. - Both baseline and endpoint can be arranged according to researcher’s needs such as clinical study design, mechanisms of tested molecules, etc. ■ Histological phenotype (including perisinusoidal fibrosis) similar to human NASH. - Clinically equivalent endpoints (reduction of NAS, no increase of fibrosis, decrease of fibrosis) can be evaluated. - Major factors (①Inflammation, ②ballooning, ③fibrosis) and their relation with prognosis (HCC) can be evaluated. ■ Virus-independent HCC pathway in steatohepatitis-background can be investigated. -13- STAMTM: In vivo predictive pharmacology model Steatosis NASH Fibrosis HCC 100% 100% 100% ① CHEMICAL ② DIET 1st hit Continuous 2nd hit - low dose streptozotocin - - high fat diet feeding - Preparing pregnant C57BL/6J mice 4w 5w 6w 7w 9w 12w 16w Birth Fatty liver evident 0w NASH evident Fibrosis* evident Nodule evident HCC evident All mice at 6 weeks of age meet Fatty change (+) “baseline” criteria as in the case ALT↑ of clinical trial in human NAFLD Activity score↑ -14- * Perisinusoidal fibrosis resemble to human NASH 12 Mechanisms of STAMTM mice 2 day 4wks 5wks 7wks 9wks 12wks 16wks 20wks Birth 0w 16 wks 〜HCC phase 12 wks 〜Nodule formation 9-12 wks: Fibrosis (to chronic fibrosis) phase 7-8 wks: Steatohepatitis phase 5-6 wks: Steatosis phase 2nd hit Continuous high fat diet feeding ■ HFD augments fat deposition in the primed liver with increased lipogenesis. ■ Fatty acid oxidation induces ROS generation, lipid peroxidation, mitochondria dysfunction. ■ Recruitment and activation of inflammatory cells (macrophages followed by fibroblasts). ■ Proliferation of hepatocytes and formation of tumor. 1st hit Inhibition of O-GlcNAc-β-N-acetylglucosaminidase of β-cell (STZ) ■ β cell-injury early after birth drives regenerative response with islet inflammation. ■ Accumulation of macrophages in the islet and adipose tissue. ■ Induction of mild diabetic condition. ■ Up-regulation of scavenger receptors and TNF-α in the liver (“priming”). -15- Examples of treatment period 4w 5w 7w 9w 12w 16w 20w Birth 0w Steatosis-targeting
Load more

Recommended publications
  • Obeticholic Acid and INT-767 Modulate Collagen Deposition in a NASH in Vitro Model Beatrice Anfuso 1, Claudio Tiribelli 1, Luciano Adorini2 & Natalia Rosso 1*
    www.nature.com/scientificreports OPEN Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model Beatrice Anfuso 1, Claudio Tiribelli 1, Luciano Adorini2 & Natalia Rosso 1* Pharmacological treatments for non-alcoholic steatohepatitis (NASH) are still unsatisfactory. Fibrosis is the most signifcant predictor of mortality and many anti-fbrotic agents are under evaluation. Herein, we assessed in vitro the efects of the FXR agonist obeticholic acid (OCA) and the dual FXR/TGR5 agonist INT-767 in a well-established co-culture NASH model. Co-cultures of human hepatoma and hepatic stellate (HSCs) cells were exposed to free fatty acids (FFAs) alone or in combination with OCA or INT-767. mRNA expression of HSCs activation markers and FXR engagement were evaluated at 24, 96 and 144 hours. Collagen deposition and metalloproteinase 2 and 9 (MMP2-9) activity were compared to tropifexor and selonsertib. FFAs induced collagen deposition and MMP2-9 activity reduction. Co- treatment with OCA or INT-767 did not afect ACTA2 and COL1A1 expression, but signifcantly reduced FXR and induced SHP expression, as expected. OCA induced a dose-dependent reduction of collagen and induced MMP2-9 activity. Similarly, INT-767 induced collagen reduction at 96 h and a slight increase in MMP2-9. Tropifexor and Selonsertib were also efective in collagen reduction but showed no modulation of MMP2-9. All tested compounds reduced collagen deposition. OCA exerted a more potent and long-lasting efect, mainly related to modulation of collagen turn-over and MMP2-9 activity. Obesity prevalence is booming in both hig- and low-income countries has led to a surge in non-alcoholic fatty liver disease (NAFLD), a condition characterized by liver steatosis.
    [Show full text]
  • Effect of Non-Alcoholic Fatty Liver Disease (Nafld) on Hepatic Drug Metabolism Enzymes in Human
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 2018 EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON HEPATIC DRUG METABOLISM ENZYMES IN HUMAN Rohitash Jamwal University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Jamwal, Rohitash, "EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON HEPATIC DRUG METABOLISM ENZYMES IN HUMAN" (2018). Open Access Dissertations. Paper 811. https://digitalcommons.uri.edu/oa_diss/811 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON HEPATIC DRUG METABOLISM ENZYMES IN HUMAN BY ROHITASH JAMWAL A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2018 DOCTOR OF PHILOSOPHY DISSERTATION OF ROHITASH JAMWAL APPROVED: Dissertation Committee Major Professor: Fatemeh Akhlaghi Navindra Seeram Ingrid Lofgren Nasser H. Zawia DEAN OF GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2018 ABSTRACT Significant changes in dietary habits have led to a rampant increase in metabolic disorders. Non-alcoholic fatty liver disease (NAFLD) is one such disorder characterized by the excess buildup of fat in hepatocytes of people who drink little or no alcohol. If not managed, NAFL (simple steatosis) progress into nonalcoholic steatohepatitis (NASH) and further deteriorate to cirrhosis leading to severe illness or even death. Drug disposition proteins (enzymes and transporters) in liver control the systemic exposure of drugs and xenobiotics in human and drive the efficacy as well as adverse events in the body.
    [Show full text]
  • What Is Non-Alcoholic Steatohepatitis (NASH)?
    What is non-alcoholic steatohepatitis (NASH)? More than just a liver disease Liver diseases are highly complex conditions driven by multiple pathways1; they are typically poorly understood, frequently overlooked and associated with a high unmet patient need worldwide. While there have been significant medical advances in viral hepatitis, non-viral liver diseases, characterized by liver inflammation and fibrosis that are often asymptomatic, have limited therapeutic options causing an increasing global chronic disease burden. One such example is non-alcoholic fatty liver disease (NAFLD). The obesity epidemic has impacted the prevalence of NAFLD across all ages globally2,3. If left untreated, over time fat build-up in the liver triggers a cycle of chronic inflammation which develops into non-alcoholic steatohepatitis (NASH) with associated fibrosis (scarring of the liver). There are currently no approved treatments for NASH, and the condition is predicted to become the leading cause of liver transplant in developed countries by 20204. The prevalence of NAFLD in Western countries is 20-30%, and it is estimated that 2-3% of the western population has NASH5. NASH: A silent disease NASH is a more severe, progressive form of NAFLD6 with generally no, or only a few, non- specific signs or symptoms. If the liver damage continues long-term, it can result in advanced fibrosis (scarring of the liver), called cirrhosis, where patients may experience symptoms such as nausea, fatigue and weight loss; with further complications leading to portal hypertension, enlarged blood vessels, enlarged spleen, mental confusion and even kidney or lung failure7. Cirrhosis leads to an increased risk of developing a type of liver cancer called hepatocellular carcinoma (HCC), as well as liver failure and, barring a transplant, significant morbidity and death7.
    [Show full text]
  • FXR Signalling: a Novel Target in Metabolic
    5 184 D P Sonne Targeting FXR in metabolic 184:5 R193–R205 Review disease MECHANISMS IN ENDOCRINOLOGY FXR signalling: a novel target in metabolic diseases Correspondence should be addressed to D P Sonne David P Sonne Email Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark david.peick.sonne@regionh. dk Abstract During the last decades, it has become clear that the gastrointestinal tract plays a pivotal role in the regulation of glucose homeostasis. More than 40 hormones originate from the gastrointestinal tract and several of these impact glucose metabolism and appetite regulation. An astonishing example of the gut’s integrative role in glucose metabolism originates from investigations into bile acid biology. From primary animal studies, it has become clear that bile acids should no longer be labelled as simple detergents necessary for lipid digestion and absorption but should also be recognised as metabolic regulators implicated in lipid, glucose and energy metabolism. The nuclear farnesoid X receptor (FXR) is a part of an exquisite bile acid-sensing system that among other things ensures the optimal size of the bile acid pool. In addition, intestinal and hepatic FXR also impact the regulation of several metabolic processes such as glucose and lipid metabolism. Accordingly, natural and synthetic FXR agonists and certain FXR- regulated factors (i.e. fibroblast growth factor 19 (FGF19)) are increasingly being evaluated as treatments for metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease (and its inflammatory version, non-alcoholic steatohepatitis). Interestingly, decreased FXR activation also benefits glucose metabolism. This can be obtained by reducing bile acid absorption using bile acid sequestering agents (approved for the treatment of type 2 diabetes) or inhibitors of intestinal bile acid transporters,that is the apical sodium-dependent bile acid transporter (ASBT).
    [Show full text]
  • PDF Document
    Histopathology and imaging analysis -SMC’s CRO services in pharmacological R&D- CONTENTS: - Company Profile (P2-) - NASH Services (P4-) - Basic Services (P12-) SMC Laboratories, Inc. smccro-lab.com Ver. 2021.1 1 Facts at a glance ■ Founded in October 2006 ■ A privately-held non-clinical CRO based in Tokyo, Japan; specialized in research on fibrosis and inflammation ■ CRO services - Non-clinical pharmacology - One of the leading CRO in liver research with Proprietary NASH-HCC (STAMTM) Model - In vivo disease models for metabolic disorders, inflammation, fibrosis and tumor - Histological imaging services - Histological scoring: NAFLD activity score, fibrosis and inflammation scores etc. - 2 - 1 CRO expertise: Leading CRO in NASH/HCC ■ SMC’s CRO services Non-clinical Histological imaging pharmacology study - High-performance pharmacology services based on the - In-house, high quality analyses; proven skills in Histology company’s specialty in fibrosis research - Elaborate and comprehensive reports by Ph.D. holders - Various lineup of disease models relating to fibrosis, inflammation, metabolic disorders and cancer - Professional support for data publication/IND application - Strategic study design proposed by experienced physicians and scientists Performance Region Number of clients 600 Europe ■ Over 600 clients worldwide Japan 500 400 ■ Over 110 peer-reviewed papers and presentations Asia North 300 America ■ 15 successful CTA packages 200 100 0 (% of the customers) - 3 - (year) Histopathology and imaging services in NASH ■Histopathological parameters are important endpoints in nonclinical as well as clinical studies in NASH and liver fibrosis. SMC’s outstanding performance in NASH/liver fibrosis research: ■As a leading CRO in NASH, SMC has accumulated know-how by assessing over 600 pharmacology studies and 60,000 slides of NASH and related diseases in mouse, rat and human.
    [Show full text]
  • 1H. Liver X Receptor-Like Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F89/2019.4 1H. Liver X receptor-like receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Donald P. McDonnell1 and Rachid Safi1 1. Duke University, USA Abstract Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [68]) are members of a steroid analogue-activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs appear to be activated by bile acids. In humans and primates, NR1H5P is a pseudogene. However, in other mammals, it encodes a functional nuclear hormone receptor that appears to be involved in cholesterol biosynthesis [71]. Contents This is a citation summary for 1H. Liver X receptor-like receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts.
    [Show full text]
  • EASL 2019 Wrap-Up Metabolic.Pptx
    Wrap-up session: Metabolic and alcohol related liver disease Fabio Marra Number of abstracts per category 160 140 120 100 80 60 40 20 0 Alcoholic liver NAFLD: NAFLD: NAFLD: NAFLD: disease Clinical Diagnostics Experimental Therapy aspects Alcohol: pathogenesis PS-173 Nagy Distinct functions for RIP3 and MLKL In murine models of ALD vs NAFL/NASH Ethanol-induced liver injury: • RIP3 drives injury independently of MLKL High fat diet-induced liver injury • MLKL drives injury independently RIP3 Alcohol: clinical aspects PS-057 Glyn-Owen Health Survey for England 2016 • Cross sectional survey of households • Designed to be representative of the general population of England • 7,826 adults of whom 3,791 (48%) provided a blood sample • 89.2% of sample had at least one risk factor for liver disease • 28.4% had two or more risk factors (alcohol>14 units/wk (112g/wk), BMI≥25, waist circumference high/very high, diabetes) • 13% of population are drinking above recommended alcohol (but not high risk alcohol) AND are obese or overweight • we call this group at risk of BAFLD = Both Alcohol And Fatty Liver Disease) • This group is often missed in clinical referral pathways from primary to secondary care PS-057 Glyn-Owen Proportion of the general population with high liver blood tests and fibrosis scores 100% 80% 60% 40% 20% representave sample Propor:on of the populaon 0% Male Female 18-24yrs 25-34yrs 35-44yrs 45-54yrs 55-64yrs 65-74yrs 75+ yrs High ALT High AST High Fib4 High APRI≥1.0 High AST:ALT rao • 10.9% had high ALT or AST (approx.
    [Show full text]
  • Combination for Therapy Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
    Recent advances in clinical practice Combination for therapy non- alcoholic steatohepatitis: rationale, opportunities Gut: first published as 10.1136/gutjnl-2019-319104 on 7 May 2020. Downloaded from and challenges Jean- François Dufour ,1,2 Cyrielle Caussy,3,4 Rohit Loomba5 1Hepatology, Department of ABStract for clinical approval of new drugs for the treat- Clinical Research, University of Non-alcoholic steatohepatitis (NASH) is becoming a ment of NASH, trials should include patients who Bern, Bern, Switzerland 2University Clinic for Visceral leading cause of cirrhosis with the burden of NASH- have significantly higher risk of progression to Surgery and Medicine, related complications projected to increase massively cirrhosis and hepatic decompensation, as defined as Inselspital, Bern, Switzerland over the coming years. Several molecules with different those who have biopsy-proven NASH with stage 2 3 Centre Hospitalier Lyon Sud, mechanisms of action are currently in development to fibrosis or higher. The regulatory approval pathway Endocrinologie Diabète et treat NASH, although reported efficacy to date has been for pharmacological therapies for NASH requires Nutrition, University Lyon 1, Hospices Civils de Lyon, Lyon, limited. Given the complexity of the pathophysiology therapies to show clinical benefit in improving France of NASH, it will take the engagement of several targets liver- related outcomes for full regulatory approval, 4 NAFLD Research Center, and pathways to improve the results of pharmacological which may take several years due to low event rates. University of California at San intervention, which provides a rationale for combination To expedite drug development, liver histological Diego, La Jolla, California, USA 5Division of Gastroenterology therapies in the treatment of NASH.
    [Show full text]
  • Study Protocol and Results
    Global Clinical Development - General Medicine LJN452 Clinical Trial Protocol CLJN452A2202 / NCT02855164 A randomized, double-blind, placebo controlled, 3- part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatohepatitis (NASH) FLIGHT-FXR Document type: Clinical Trial Protocol EUDRACT number: 2015-005215-33 Version number: 03 (Clean) Clinical trial phase: II Release date: 05-Oct-2017 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Clinical Trial Protocol Template Version 3.2 (July 2016) Novartis Confidential Page 2 Clinical Trial Protocol v03 (Clean) Protocol No. CLJN452A2202 Table of contents Table of contents .................................................................................................................2 List of tables ........................................................................................................................6 List of figures ......................................................................................................................7 List of abbreviations ............................................................................................................8 Glossary of terms...............................................................................................................12 Amendment 3 (05-Oct-2017) ............................................................................................13
    [Show full text]
  • Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
    Review Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension Eric Kalo 1 , Scott Read 1,2,3,† and Golo Ahlenstiel 1,2,3,*,† 1 Blacktown Clinical School, School of Medicine, Western Sydney University, Blacktown, NSW 2148, Australia; [email protected] (E.K.); [email protected] (S.R.) 2 Blacktown Hospital, Blacktown, NSW 2148, Australia 3 Storr Liver Centre, The Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia * Correspondence: [email protected]; Tel.: +61-2-9851-6073; Fax: +61-2-9851-6050 † These authors contribute equally to this work. Abstract: Antifibrotic therapies for the treatment of liver fibrosis represent an unconquered area of drug development. The significant involvement of the gut microbiota as a driving force in a multitude of liver disease, be it pathogenesis or fibrotic progression, suggest that targeting the gut–liver axis, relevant signaling pathways, and/or manipulation of the gut’s commensal microbial composition and its metabolites may offer opportunities for biomarker discovery, novel therapies and personalized medicine development. Here, we review potential links between bacterial translocation and deficits of host-microbiome compartmentalization and liver fibrosis that occur in settings of advanced chronic liver disease. We discuss established and emerging therapeutic strategies, translated from our current knowledge of the gut–liver axis, targeted at restoring intestinal eubiosis, ameliorating hepatic fibrosis and rising portal hypertension that characterize and define the course of decompensated cirrhosis. Keywords: liver fibrosis; portal hypertension; microbiota; cirrhosis; chronic liver disease; gut–liver Citation: Kalo, E.; Read, S.; Ahlenstiel, G. Targeting Gut–Liver axis; bacterial translocation; hepatic macrophages; PRRs; TLRs Axis for Treatment of Liver Fibrosis and Portal Hypertension.
    [Show full text]
  • Bioactive Compound Library Plus (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Bioactive Compound Library Plus (96-well) Product Details: Catalog Number: CS-L001P Formulation: A collection of 13195 bioactive compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L001P-Part A-1 1 2 3 4 5 6 7 8 9 10 11 12 SKF-96365 Fumarate MRT68921 a Empty (hydrochlorid ML162 ML-210 hydratase-IN- (dihydrochlori Vonoprazan Peretinoin Ufenamate SR-3029 CBR-5884 Empty e) 1 de) (1R,2R)-2- 2-PCCA HLCL-61 b Empty PCCA (hydrochlorid Mivebresib AZD0156 BAY-876 BAY1125976 BAY-1436032 Tomivosertib LY3177833 (hydrochlorid Empty (hydrochlorid e) e) Ro 41-1049 c Empty PQR620 (hydrochlorid AT-130 Bay 41-4109 PD 117519 NSC 663284 MK-4101 YYA-021 Faropenem Bromobimane Empty e) (racemate) daloxate Flavopiridol 2- 9- (Z)-9- Dolutegravir d Empty Flavopiridol (Hydrochlorid (Dimethylami NPS-2143 Propenyladen Propenyladen SNS-032 intermediate- Semagacesta Ko 143 Empty e) no)acetaldeh ine ine 1 t AT2 receptor Mitoquinone JNJ- e Empty KNK437 GLX351322 agonist C21 TA-01 TA-02 (mesylate) BW-A 78U AZD-5438 Tubercidin 17203212 Empty N-[(4- Taranabant f Empty Taranabant Aminophenyl) GSK481 Taranabant ((1R,2R)stere R547 Pipequaline Pirozadil PAP-1 4-IBP Empty methyl]adeno (racemate) oisomer) Toll-like g Empty E 2012 SDZ-MKS BAPTA SCH 546738 receptor Delpazolid DSM265 GSK- Varenicline SAR-020106
    [Show full text]
  • FXR Agonists As Therapeutic Options for NAFLD/NASH and Their Clinical Trial Status
    FXR Agonists as Therapeutic Options for NAFLD/NASH and their Clinical Trial Status Syeda Maliha, Grace L. Guo Rutgers, The State University of New Jersey The farnesoid X receptor (FXR) is a nuclear receptor expressed highly in the liver and intestine. FXR is a transcriptional regulator activated endogenously by bile acids and regulates the expression of genes involved in cholesterol and bile acid homeostasis (via CYP7A1), hepatic gluconeogenesis/lipogenesis, and inflammation. The purpose of this study was to evaluate therapeutic targets that utilize FXR activation to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatosis (NASH) using literature review of current preclinical studies in mice and clinical research. NASH is characterized by hepatic steatosis, cellular damage, inflammation and progressive development of liver fibrosis and the potential to progress to hepatocellular carcinoma. However, there is currently no FDA approved treatment option for NASH. While there are multiple factors contributing to NASH pathophysiology, bile acid regulation is proposed to have a major role in NASH onset. FXR agonists are currently in phase two or phase three clinical trials and these ligands have demonstrated improvement on NASH symptoms. The forerunner of these candidates is obeticholic acid (OCA) where the treatment group observed a significant decrease in NAFLD activity score compared to placebo group. A concern with OCA is pruritis and unfavorable alterations in cholesterol levels. Other agonists like cilofexor, tropifexor, nidufexor, and EDP-305 have displayed favorable effects on NAFLD/NASH with similar or without the same side effects as OCA. FXR antagonism has also been studied, but antagonists like ursodeoxycholic acid (UDCA) and glycine-β-muricholic acid (Gly-MCA) are in pre-clinical stages.
    [Show full text]